Skip to main content

You are here:

BUR02

This study aims to establish the long-term safety and tolerability profile of Burosumab in the treatment of adults with XLH and to provide continued treatment for subjects previously enrolled in UX023-CL303 and UX023-CL304 clinical trials.

Therapeutic Area
Endocrine
Type of Study
Phase 3b Open-label Study
Study Status
Open Recruiting
Sponsor
Kyowa Kirin
Principal Investigator
Dr Rachel Crowley
Contact
laura.feeney@ucd.ie